A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma

NCT01976286 | Active Not Recruiting DMC

• 1 other identifier: STU84250
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to find out the safety and effectiveness of Glycolic Acid Chemical Peels compared to Salicylic Acid Chemical Peels for the treatment of melasma.

Conditions

Melanosis

Outcome Measures

Primary Outcomes (1)

• Change in best overall cosmetic appearance (right side or left side better)rated by a blinded dermatologist from baseline to week 16

  The primary outcome was a blinded rating of the treatment area (Salicylic Acid Peels Versus Glycolic Acid Peels) with the best overall cosmetic appearance. A dermatologist will blindly evaluate the treated areas of each side from live subjects at baseline and on the final follow up visit (week 16).

  1 hour at baseline and week 16

Study Arms (2)

Salicylic Acid Peels

ACTIVE COMPARATOR

Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.

Other: Salicylic Acid Peels

Glycolic Acid Peels

ACTIVE COMPARATOR

Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.

Other: Glycolic Acid Peels

Interventions

Salicylic Acid Peels OTHER

Salicylic Acid Peels

Glycolic Acid Peels OTHER

Glycolic Acid Peels

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects aged 18 years or older
• Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
• Subjects in general good health
• Subjects must be willing and able to understand and provide informed consent for the use of their tissue and communicate with the investigator
• Subjects must be willing to not apply other treatment options for melasma during the course of the study

You may not qualify if:

• Subjects under 18 years of age
• Subjects who are pregnant and/or lactating
• Subjects who are unable to understand the protocol or to give informed consent
• Subjects diagnosed with mental illness
• Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
• Subjects who have had a chemical peel in the past 3 months
• Subjects who have used a prescribed retinoid in the past 3 months
• Subjects with a bleeding disorder
• Subjects with a history of abnormal wound healing
• Subjects with a history of abnormal scarring

Sponsors & Collaborators

• Northwestern University: lead

Study Sites (1)

Northwestern University Department of Dermatology

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Melanosis

Condition Hierarchy (Ancestors)

Hyperpigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Murad Alam, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor in Dermatology, Otolaryngology - Head and Neck Surgery, and Surgery-Organ Transplantation

Study Record Dates

• First Submitted: October 15, 2013
• First Posted: November 5, 2013
• Study Start: January 1, 2015
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: January 31, 2025

Record last verified: 2025-01

Locations

US (1)